Trials / Not Yet Recruiting
Not Yet RecruitingNCT07019090
Long-term Safety and Efficacy Study of HSK44459 Tablets in Patients With Idiopathic Pulmonary Fibrosis (IPF)
An Open-label Extension Trial of the Long-term Safety and Efficacy of HSK44459 Tablets in Patients With Idiopathic Pulmonary Fibrosis (IPF)
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 120 (estimated)
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd. · Industry
- Sex
- All
- Age
- 40 Years
- Healthy volunteers
- Not accepted
Summary
This study is open to people with idiopathic pulmonary fibrosis (IPF) . They can only take part if they have completed treatment in a previous study with a medicine called HSK44459. The primary object of this study is to find out how well people with idiopathic pulmonary fibrosis (IPF) tolerate long- term treatment with HSK44459.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HSK44459 | HSK44459 |
Timeline
- Start date
- 2025-06-27
- Primary completion
- 2026-10-31
- Completion
- 2027-01-19
- First posted
- 2025-06-13
- Last updated
- 2025-06-13
Source: ClinicalTrials.gov record NCT07019090. Inclusion in this directory is not an endorsement.